Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)

This is an open label, Phase 1/2 study of oral ARQ 092 (Miransertib) administered to subjects at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) (MOSAIC).

Children's National Hospital
 (6.2 away) Contact site
  • 160 views
  • 23 Sep, 2020
  • +30 other locations
Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

measurable disease
renal function
cancer
cfdna
ret inhibitor
Johns Hopkins Kimmel Cancer Center
 (8.2 away) Contact site
  • 1244 views
  • 08 Jul, 2020
  • +90 other locations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations …

measurable disease
major surgery
lung cancer
cancer
solid tumour
Maryland Oncology Hematology
 (7.4 away) Contact site
  • 144 views
  • 14 Oct, 2020
  • +54 other locations
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

metastatic cancer
medullary thyroid carcinoma
antineoplastic agents
lung cancer
platinum-based chemotherapy
Georgetown University Medical Center
 (7.9 away) Contact site
  • 1632 views
  • 31 Aug, 2020
  • +92 other locations
Durvalumab and Tremelimumab for Pediatric Malignancies

The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.

durvalumab
acute leukemia
cancer
lymphoma
leukemia
Research Site
 (5.4 away) Contact site
  • 15 views
  • 26 Aug, 2020
  • +23 other locations
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary tumors.

vegf
renal function
platelet count
vascular endothelial growth factor
neutrophil count
Georgetown University Medical Center
 (7.9 away) Contact site
  • 0 views
  • 25 Nov, 2020
  • +62 other locations
Derazantinib and Atezolizumab in Patients With Urothelial Cancer

The purpose of this study is to evaluate efficacy of derazantinib single-agent or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.

measurable disease
advanced urothelial carcinoma
renal function
growth factor
atezolizumab
Inje University Haeundae Paik Hospital
 (6.9 away) Contact site
  • 9 views
  • 28 Oct, 2020
  • +89 other locations
Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not …

flt3 internal tandem duplication
induction chemotherapy
fludarabine
cancer
remission
Children's National Medical Center
 (5.4 away) Contact site
  • 39 views
  • 11 Nov, 2020
  • +30 other locations
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults

The primary objectives of the study are: To describe the safety profile of each of the 3 dosages of vYF and of YF-VAX within the 28 days post-vaccination and up to the 6 months (Day 180) post-vaccination visit To describe the antibody responses elicited by each of the 3 dosages …

Investigational Site Number 8400001
 (6.2 away) Contact site
  • 8 views
  • 17 Sep, 2020
  • 1 location
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform …

measurable disease
neutrophil count
cancer
vinorelbine
filgrastim
Children's National Medical Center
 (5.3 away) Contact site
  • 3 views
  • 25 Nov, 2020
  • +61 other locations